Why the study?
Cardiovascular disease from accelerated atherosclerosis is the major cause of morbidity and premature mortality in type 1 diabetes, but little information is available to quantify early atherosclerosis.
This review highlights the critical need for better tools and strategies to detect and manage early atherosclerosis in patients with type 1 diabetes to prevent premature cardiovascular mortality.
May inform T1D atherosclerosis screening; leaves open optimal tests and interventions pending validation.
The major cause of morbidity and often premature mortality in people with type I diabetes (T1D) is cardiovascular disease owing to accelerated atherosclerosis. We review publications relating to the rationale behind, and clinical tests for, detecting and treating early atherosclerosis in people with T1D. Currently available tools for atherosclerosis assessment include risk equations using vascular risk factors, arterial intima-media thickness, the ankle-brachial index, coronary artery calcification and angiography, and for more advanced lesions, intravascular ultrasound and optical coherence tomography. Evolving research tools include risk equations incorporating novel clinical, biochemical and molecular tests; vascular MRI and molecular imaging. As yet there is little information available to quantify early atherosclerosis. With better means to control the vascular risk factors, such as hypertension, dyslipidaemia and glycaemic control, and emerging therapies to control novel risk factors, further epidemiologic and clinical trials are merited to facilitate the translation into clinical practice of robust means to detect, monitor and treat early atherosclerosis in those with T1D.
No takes yet. Share an insight, caveat, or question.
Jenkins et al. (2019) studied this question.